65,437 trials
Sinusitis
Primary: the Effect of Squeezable Bottle and Syringe on Clinical Effectiveness in Sinusitis Children — 6.56; 6.89; 2.17; 1.24 units on a scale — p=<0.05
Healthy
Primary: Change in Exhaled Inflammatory Mediator Levels — 1.42 pg/mL
Peripheral Vascular Disease · Embolism and Thrombosis · Venous Thrombosis
Primary: Change in Degree of Occlusion From Baseline to Final Angiogram/Venogram. — 1.31; 1.33; 1.36; 1.80 Units on a Scale — p=<0.0001
Intubation; Difficult
Primary: The Differences in the Glottis View (C&L Grade) of Macintosh Laryngoscope and GVL Selected by Weight. — 6; 5.5 units on a scale — p=<0.05
Chronic Idiopathic Urticaria
Primary: Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin — 18.14; 15.17; 13.40; 20.19 FcεRI positive skin…
Restless Legs Syndrome · End-Stage Renal Disease
Primary: Ratio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI) — 1.16; 0.51 ratio — p=0.0232
Chronic Hepatitis C
Primary: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 50.0 percentage of subjects achieving SVR
Idiopathic Pulmonary Fibrosis
Primary: Safety and Tolerability — 0; 0; 0; 0 participants
Chronic Hepatitis C
Primary: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 88.0 percentage of subjects achieving SVR
Influenza · Fever
Primary: Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination. — 422; 202; 370; 160 Subjects
Obstructive Sleep Apnea
Primary: Positive Airway Pressure Adherence (Nightly Use of Treatment) — 3.99; 4.45 hours — p== 0.27
Memory Disorders
Primary: Cerebral Glutamate Concentration — 1.34; 1.34 ratio
Tumor Lysis Syndrome
Primary: Serum Uric Acid (sUA) Level Control — 514.0; 708.0 mg x hour/dL — p=<0.0001
HIV Infections
Primary: Plasma Concentration of Raltegravir at 12 Hours (C 12 Hrs) in Part 1 — 241.35; 96.29; 92.22 nM — p=0.507
Pancreatic Cancer
Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients